Celcuity (CELC) Enterprise Value (2017 - 2026)
Celcuity's (CELC) quarterly Enterprise Value came in at -$717.3 million in Q4 2025, down 205.1% YoY from $682.5 million in Q4 2024, and down 57.66% on a QoQ basis from -$455.0 million in Q3 2025.
Analysis
Celcuity (CELC) Enterprise Value (2017 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Enterprise Value data on file, last reported at -$717.3 million in Q4 2025.
- Quarterly Enterprise Value fell 205.1% year-over-year to -$717.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$717.3 million (down 205.1% YoY) and the FY2025 annual result came in at -$717.3 million, down 205.1% from the prior year.
- Enterprise Value slipped to -$717.3 million in Q4 2025, from -$455.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$35.0 million in Q1 2021 to a low of -$717.3 million in Q4 2025.
- A 5-year average of -$187.4 million and a median of -$162.9 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value tumbled 623.06% — and 2025, when it jumped 40.51%.
- Tracing CELC's Enterprise Value over 5 years: stood at -$84.3 million in 2021, then sank by 99.97% to -$168.6 million in 2022, then declined by 7.12% to -$180.6 million in 2023, then plunged by 30.19% to -$235.1 million in 2024, then sank by 205.1% to -$717.3 million in 2025.
- The last three Enterprise Value figures came in at -$717.3 million (Q4 2025), -$455.0 million (Q3 2025), and -$168.4 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Celcuity | 5.25 Bn | 5.25 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.79 Bn |
| Dec 31, 2025 | 4.37 Bn |
| Sep 30, 2025 | 1.68 Bn |
| Jun 30, 2025 | 351.12 Mn |
| Mar 31, 2025 | 176.87 Mn |
| Dec 31, 2024 | 251.09 Mn |
| Sep 30, 2024 | 289.34 Mn |
| Jun 30, 2024 | 323.23 Mn |
| Mar 31, 2024 | 487.05 Mn |
| Dec 31, 2023 | 191.04 Mn |
| Sep 30, 2023 | 70.52 Mn |
| Jun 30, 2023 | 96.22 Mn |
| Mar 31, 2023 | 67.42 Mn |
| Dec 31, 2022 | 47.43 Mn |
| Sep 30, 2022 | 92.52 Mn |
| Jun 30, 2022 | 69.03 Mn |
| Mar 31, 2022 | 61.19 Mn |
| Dec 31, 2021 | 112.47 Mn |
| Sep 30, 2021 | 177.92 Mn |
| Jun 30, 2021 | 262.06 Mn |